Xinjing Zhiyuan Biotechnology

Xinjing Zhiyuan is a Beijing-based biotechnology company specializing in the development of next-generation covalent small molecule therapeutics. The company leverages its proprietary Neo-Covalent platform, which integrates chemical proteomics, structural biology, and computational chemistry to address 'undruggable' targets. Its primary focus is on high-impact areas such as oncology and immunology, with a particular emphasis on targeting KRAS mutations and other key signaling proteins. Founded by Dr. Pan Shifeng, a former Novartis executive, the company is backed by prominent investors including Sequoia China and 5Y Capital. Xinjing Zhiyuan aims to overcome the limitations of traditional drug discovery by creating highly selective and potent inhibitors for challenging biological targets.